Technical Data
I7662-14T
Interferon beta 1 (beta 1b), Recombinant, Human (IFNb1, IFNb1b)
10ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Recombinant protein corresponding to 165aa of human Interferon-beta 1b expressed in E.coli is a single, non-glycosylated mutein (variant form) of human Interferon beta-1b polypeptide chain.

Biological Activity:
The specific activity as determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus) was found to be 32x10^6 IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.493 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of IFN-beta as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~18.5kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder from a solution containing 50mg human albumin and 50mg dextrose. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005 Dec;11(6):658-68. 2. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. J Neurol 2005 Sep;252 Suppl 3:iii28-iii33. 3. 10 years of interferon beta-1b (Beta feron therapy. J Neurol 2005 Sep;252 Suppl 3:iii1-iii2. 4. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005 Nov;62(11):1684-8. 5. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b. Australas J Dermatol 2005 Aug;46(3):202-4. 6. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol 2005 Aug;46(3):154-7.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.